Amoebicidal thymol analogues against brain-eating amoeba, Naegleria fowleri

Meriam Ben Youssef1, Amani Omrani1, Ines Sifaoui2

  • 1Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, 38296 La Laguna, Tenerife, Spain; Laboratory of Functional Physiology and Valorization of Bio-Ressources, Higher Institute of Biotechnology of Beja, University of Jendouba, Beja 382-9000, Tunisia; Instituto Universitario de Bio-Orgánica Antonio González, and Departamento de Química Orgánica, Universidad de La Laguna, Avenida Astrofísico Francisco Sánchez 2, 38206 La Laguna, Tenerife, Spain.

Bioorganic Chemistry
|March 19, 2025
PubMed

Insights

New thymol derivatives show promise against the brain-eating amoeba, Naegleria fowleri. Compound 8 effectively killed amoeba stages with low mammal cell toxicity, suggesting potential for new treatments.

Area of Science:

  • Medicinal Chemistry
  • Parasitology
  • Drug Discovery

Background:

  • Naegleria fowleri causes fatal primary amoebic meningoencephalitis.
  • Current therapies for Naegleria infections are largely ineffective.
  • Natural products offer a promising avenue for novel amoebicidal drug development.

Purpose of the Study:

  • To synthesize and screen thymol derivatives as potential amoebicidal agents against Naegleria fowleri.
  • To evaluate the cytotoxicity and selectivity of these derivatives on mammalian cells.
  • To investigate the mechanism of action and pharmacokinetic properties of the most potent compound.

Main Methods:

  • Synthesis of eight monoterpene phenol derivatives of thymol.
  • Screening of compounds against Naegleria fowleri trophozoites and cysts.
  • Cytotoxicity assessment on murine macrophage cell line J774.
  • Mechanism of action studies including calcium, mitochondrial, membrane, chromatin, and ROS analysis.
  • In-silico ADME analysis for drug-likeness.

Main Results:

  • Compounds 3, 4, 7, and 8 demonstrated significant activity against N. fowleri.
  • 4-nitrophenyl thymyl carbonate 8 exhibited the highest potency (IC50: 22.87 μM for trophozoites, 25.16 μM for cysts) with low cytotoxicity.
  • Derivative 8 induced programmed cell death via multiple cellular pathways.
  • In-silico analysis confirmed excellent drug-likeness and pharmacokinetic properties for derivative 8.

Conclusions:

  • Thymol derivative 8 is a highly promising candidate for developing new drugs against Naegleria infections.
  • The compound's potent amoebicidal activity, low cytotoxicity, and favorable pharmacokinetic profile warrant further investigation.
  • This study highlights the potential of natural product derivatives in addressing unmet medical needs for parasitic infections.

Related Concept Videos

Biological Methods for Microbial Control01:28

Biological Methods for Microbial Control

Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...